Idorsia Company Profile
What is the competitive landscape for IDORSIA
IDORSIA has two approved drugs.
There are nine US patents protecting IDORSIA drugs.
Summary for Idorsia
| US Patents: | 9 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Idorsia
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-002 | Apr 7, 2022 | RX | Yes | Yes | 9,732,075 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Idorsia | TRYVIO | aprocitentan | TABLET;ORAL | 217686-001 | Mar 19, 2024 | RX | Yes | Yes | 12,297,189 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-001 | Apr 7, 2022 | RX | Yes | No | 9,790,208 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-002 | Apr 7, 2022 | RX | Yes | Yes | 9,790,208 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Idorsia Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Chile | 2019002470 | ⤷ Start Trial |
| South Korea | 20190119635 | ⤷ Start Trial |
| Hungary | E069231 | ⤷ Start Trial |
| European Patent Office | 2855453 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Idorsia Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2190837 | 2490038-3 | Sweden | ⤷ Start Trial | PRODUCT NAME: APROCITENTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/24/1818 20240627 |
| 2855453 | 36/2022 | Austria | ⤷ Start Trial | PRODUCT NAME: DARIDOREXANT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE DARIDOREXANTHYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1638 (MITTEILUNG) 20220502 |
| 2190837 | CR 2024 00046 | Denmark | ⤷ Start Trial | PRODUCT NAME: APROCITENTAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/24/1818 20240628 |
| 2190837 | 24C1047 | France | ⤷ Start Trial | PRODUCT NAME: APROCITENTAN OU L'UN DE SES SELS; REGISTRATION NO/DATE: EU/1/24/1818 20240628 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
